PortfoliosLab logoPortfoliosLab logo
BCRX vs. XOM
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

BCRX vs. XOM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in BioCryst Pharmaceuticals, Inc. (BCRX) and Exxon Mobil Corporation (XOM). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, BCRX achieves a 33.97% return, which is significantly higher than XOM's 16.96% return. Over the past 10 years, BCRX has outperformed XOM with an annualized return of 13.03%, while XOM has yielded a comparatively lower 8.48% annualized return.


BCRX

1D
-2.52%
1M
20.11%
6M
41.22%
YTD
33.97%
1Y
19.29%
3Y*
13.27%
5Y*
-8.57%
10Y*
13.03%

XOM

1D
1.03%
1M
-5.53%
6M
12.96%
YTD
16.96%
1Y
24.15%
3Y*
13.15%
5Y*
22.21%
10Y*
8.48%
*Multi-year figures are annualized to reflect compound growth (CAGR)

BCRX vs. XOM - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
BCRX
BioCryst Pharmaceuticals, Inc.
33.97%3.72%25.54%-47.82%-17.11%85.91%115.94%-57.25%64.36%-22.43%
XOM
Exxon Mobil Corporation
16.96%15.98%11.26%-6.26%87.41%57.58%-36.21%7.23%-15.09%-3.81%

Correlation

The correlation between BCRX and XOM is -0.09, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

-0.09

Correlation (3Y)
Calculated over the trailing 3-year period

0.04

Correlation (5Y)
Calculated over the trailing 5-year period

0.12

Correlation (10Y)
Calculated over the trailing 10-year period

0.16

Correlation (All Time)
Calculated using the full available price history since Mar 4, 1994

0.15

The correlation between BCRX and XOM shifts across timeframes, from -0.09 (1 year) to 0.16 (10 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

BCRX:

$2.19B

XOM:

$575.42B

EPS

BCRX:

-$2.02

XOM:

$5.96

PS Ratio

BCRX:

2.68

XOM:

1.81

Total Revenue (TTM)

BCRX:

$885.72M

XOM:

$326.01B

Gross Profit (TTM)

BCRX:

$167.34M

XOM:

$83.11B

EBITDA (TTM)

BCRX:

-$374.88M

XOM:

$60.44B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

BCRX vs. XOM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BCRX
BCRX Risk / Return Rank: 5858
Overall Rank
BCRX Sharpe Ratio Rank: 5959
Sharpe Ratio Rank
BCRX Sortino Ratio Rank: 5858
Sortino Ratio Rank
BCRX Omega Ratio Rank: 5454
Omega Ratio Rank
BCRX Calmar Ratio Rank: 5959
Calmar Ratio Rank
BCRX Martin Ratio Rank: 5858
Martin Ratio Rank

XOM
XOM Risk / Return Rank: 7171
Overall Rank
XOM Sharpe Ratio Rank: 7676
Sharpe Ratio Rank
XOM Sortino Ratio Rank: 6969
Sortino Ratio Rank
XOM Omega Ratio Rank: 6868
Omega Ratio Rank
XOM Calmar Ratio Rank: 7070
Calmar Ratio Rank
XOM Martin Ratio Rank: 7272
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BCRX vs. XOM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for BioCryst Pharmaceuticals, Inc. (BCRX) and Exxon Mobil Corporation (XOM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


BCRXXOMDifference
Sharpe ratioReturn per unit of total volatility

-0.62

Sortino ratioReturn per unit of downside risk

-0.48

Omega ratioGain probability vs. loss probability

1.11

1.18

-0.07

Calmar ratioReturn relative to maximum drawdown

0.58

1.23

-0.65

Martin ratioReturn relative to average drawdown

1.20

3.24

-2.03

BCRX vs. XOM - Sharpe Ratio Comparison

The current BCRX Sharpe Ratio is 0.38, which is lower than the XOM Sharpe Ratio of 1.00. The chart below compares the historical Sharpe Ratios of BCRX and XOM, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

BCRX vs. XOM - Drawdown Comparison

The maximum BCRX drawdown since its inception was -97.74%, which is greater than XOM's maximum drawdown of -62.40%. Use the drawdown chart below to compare losses from any high point for BCRX and XOM.


Loading charts...

Drawdown Indicators


BCRXXOMDifference

Max Drawdown

Largest peak-to-trough decline

-97.74%

-62.40%

-35.34%

Max Drawdown (1Y)

Largest decline over 1 year

-30.36%

-20.11%

-10.25%

Max Drawdown (3Y)

Largest decline over 3 years

-47.85%

-20.11%

-27.74%

Max Drawdown (5Y)

Largest decline over 5 years

-79.10%

-20.51%

-58.59%

Max Drawdown (10Y)

Largest decline over 10 years

-83.69%

-61.34%

-22.35%

Current Drawdown

Current decline from peak

-68.46%

-18.46%

-50.00%

Average Drawdown

Average peak-to-trough decline

-69.64%

-10.22%

-59.42%

Ulcer Index

Depth and duration of drawdowns from previous peaks

14.73%

7.65%

+7.08%

Volatility

BCRX vs. XOM - Volatility Comparison

BioCryst Pharmaceuticals, Inc. (BCRX) has a higher volatility of 15.21% compared to Exxon Mobil Corporation (XOM) at 7.89%. This indicates that BCRX's price experiences larger fluctuations and is considered to be riskier than XOM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


BCRXXOMDifference

Volatility (1M)

Calculated over the trailing 1-month period

15.21%

7.89%

+7.32%

Volatility (6M)

Calculated over the trailing 6-month period

36.41%

20.76%

+15.65%

Volatility (1Y)

Calculated over the trailing 1-year period

46.57%

24.73%

+21.84%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

62.20%

26.71%

+35.49%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

72.65%

28.25%

+44.40%

Dividends

BCRX vs. XOM - Dividend Comparison

BCRX has not paid dividends to shareholders, while XOM's dividend yield for the trailing twelve months is around 2.94%.


PositionTTM20252024202320222021202020192018201720162015
BCRX
BioCryst Pharmaceuticals, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
XOM
Exxon Mobil Corporation
2.94%3.32%3.57%3.68%3.22%5.70%8.44%4.92%4.74%3.66%3.30%3.69%

Financials

BCRX vs. XOM - Financials Comparison

This section allows you to compare key financial metrics between BioCryst Pharmaceuticals, Inc. and Exxon Mobil Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00B40.00B60.00B80.00B100.00B120.00BJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober2026
156.41M
83.16B
(BCRX) Total Revenue
(XOM) Total Revenue
Values in USD except per share items

Frequently Asked Questions


BCRX and XOM have a correlation of -0.09, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

BCRX has higher volatility (15.21%) compared to XOM (7.89%). In terms of maximum drawdown, BCRX dropped -97.74% vs XOM's -62.40%.

XOM currently has the higher Sharpe Ratio (1.00 vs 0.38), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for BCRX and XOM

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer